← All trials
NCT01592370
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 27, 2012
- Primary completion
- Oct 15, 2018
- Completion date
- Mar 16, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 375
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Bristol-Myers SquibbLead sponsor
- Bristol-Myers SquibbStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.